| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.13 | 0.004 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.004 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | 0.092 | 0.005 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.005 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | 0.1 | 0.005 |
| mRNA | chlorambucil | CTRPv2 | pan-cancer | AAC | 0.094 | 0.005 |
| mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | 0.096 | 0.005 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.006 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.007 |